Rheumatology

Article	Citations
P070 Evaluation of the perception of pediatric rheumatology by pediatric residents: results of a national survey	102
P137 Epidemiological study of influenza vaccination and RA	98
P205 The contemporary presentation and management of giant cell arteritis with large vessel vasculitis	89
67 Double impact: hypophosphatemic rickets and vitamin D intoxication	81
P018 Non-alcoholic fatty liver disease in spondyloarthritis: identifying patients on therapy at high risk of serious liver disease	76
P103 The impact of the COVID-19 pandemic on primary care referrals and new diagnoses of inflammatory arthritis	75
E010 Checkpoint inhibitor-induced rheumatological adverse events: real-world experience from Northeast England	72
E053 Effectiveness of colchicine among patients with COVID-19 infection: a randomised, open labelled, clinical trial	70
E078 Inflammation modifies the effect of rheumatoid arthritis in overall mortality among females	69
OA02 Real-world experience of dose tapering TNF inhibitors in rheumatoid arthritis: Long-term results	64
P186 Long-term safety of ixekizumab in adult patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis	56
P107 Long-term efficacy of baricitinib in patients with rheumatoid arthritis with inadequate response to bDMARDs: results from RA-BEYOND up to 6.9-years of treatment	56
P045 Development and evaluation of machine learning algorithms for the prediction of opioid-related deaths among UK patients with non-cancer pain	55
P110 Challenges of meeting NICE guidance for rheumatoid arthritis in the modern era: a service audit	55
E058 The effects of a pain management programme for patients with an inflammatory arthritis	53
E063 Cardiac amyloidosis: a case series of 31 patients with a comprehensive literature review	52
P139 Rituximab in a large UK centre during the COVID-19 pandemic: the effects of employing a reduced dosing regimen on clinical response in Rheumatoid Arthritis patients	51
P071 Exercise as an anti-inflammatory treatment in axial spondyloarthritis (axSpA): a proof-of-concept study	50
P166 Parotid benign lymphoepithelial cyst in connective tissue disease: a rare case series and literature review	48
P104 The role of occupational therapy for the self-management of rheumatoid arthritis: a mixed methods systematic review	47
P193 Bimekizumab improves key symptoms, disease activity and function in patients across the full spectrum of axial spondyloarthritis up to week 24: results from two phase 3 studies	47
P007 Automating blood monitoring and handover for patients with rheumatic diseases commencing disease-modifying anti-rheumatic drugs (DMARDs)	47
P012 Using the BSR Lupus audit as a springboard to improve management of SLE in the outpatient clinic	46
E027 An outlandish presentation of IgG4-related disease	46
P068 The effects of exercise and physical activity in inflammatory rheumatic diseases: a scoping literature review	45

P054 Utilising a pharmacist-designed best value biologic and targeted synthetic shared decision-making tool to empower patients, support clinicians and save NHS resources	45
P010 Real world experience of switching to an adalimumab biosimilar; different outcomes for axial spondylitis, psoriatic and rheumatoid arthritis	43
P124 Rheumatoid Arthritis with Normal CRP: an Underappreciated, Persistent Phenotype: Equally at Risk of Severe Disease	43
P183 Disease activity, comorbidities and functional status predict treatment response to biologic and targeted synthetic disease-modifying anti-rheumatic drugs in psoriatic arthritis	43
P105 Mode of hospital rheumatology appointments in people with rheumatoid arthritis: the impact of the pandemic in England	42
OA03 Harnessing quantitative proteomics to identify biomarkers of treatment response to etanercept in patients with rheumatoid arthritis	42
OA17 Patient values and what matters to patients with axial spondyloarthritis in clinic	40
P095 Fibromyalgia correlates with neurodivergent traits in a self-selected community population	40
E072 Real-world single-centre experience of JAK inhibitor use in RA	40
P198 Intracardiac thrombosis and vascular involvement in Behçet's disease: two sides of the same coin?	40
P053 Patient engagement in long-term PROMs collection: 48-month observation in real-world clinical practice	40
P056 Analysis of antibody response to SARS-CoV-2 vaccination and natural infection in a tertiary centre cohort of lupus nephritis patients	39
E011 What information should we provide to inform and empower our patients to participate in shared decision making? The patient perspective	39
OA32 Jaw claudication - does the textbook description need updating?	38
P070 Results of a consensus process to determine the elements of a complex digital intervention for distal upper limb musculoskeletal disorders	37
P127 Baricitinib Efficacy in Moderate Rheumatoid Arthritis - A Post-hoc Analysis from two Phase III Trials	37
P195 Use of the Giant Cell Arteritis Score (GCAPS) in a district general hospital	36
P043 Income-Related Health Inequality and Osteoarthritis Intervention Outcomes: a Cohort Study	36
P072 Significant functional impairment and disability in individuals with psoriatic arthritis and Achilles tendon pain	36
E082 A review of the development of gangrene in patients with systemic lupus erythematosus: a 44-year follow-up study	36
P086 Service evaluation of ultrasound use in patients with juvenile idiopathic arthritis in a UK tertiary paediatric rheumatology centre, as the first step towards developing an evidence-based guideli	36
P009 Navigating giant cell arteritis (GCA) service during and post COVID-19 pandemic: an audit of GCA care at North Bristol NHS Trust against the BSR quality standards	35
P058 Pneumocystis Jirovecii Infection in autoimmune inflammatory rheumatic diseases in Oxford	35
E049 The Initial Impacts of the UK-Wide Rheumatology Physiotherapy Capabilities Framework	35
P148 Long-term survival of patients with idiopathic inflammatory myopathies: Anatomy of a single-center cohort	34
P082 Research priorities regarding the use of bisphosphonates for osteoporosis: a UK priority setting exercise	34
O08 Developing a DNA methylation signature for predicting rheumatoid arthritis using a machine learning pipeline	33
O14 Frequency and site of clinically unsuspected synovitis on whole-body MRI in juvenile idiopathic arthritis	33
Trends in risk factor control in patients with gout: data from the National Health and Nutrition Examination Survey, 2007–2018	33
P263 Autoantibodies in ankylosing spondylitis: a systematic literature review	31
Comment on: Refining myositis associated with primary Sjögren’s syndrome: data from the prospective cohort ASSESS	31
P069 Assessment of diagnostic delay for hip disorders in the pediatric population	31
Is adipose-tissue (or its fraction) grafting really effective in the treatment of scleroderma hand?	31
P076 SARS-COV-2 infection in two patients with juvenile lupus	31
OA02 A cohort of 79 children with Paediatric multisystem inflammatory syndrome associated with COVID-19	30
P120 A collaborative approach to rolling out advice and guidance	30
P239 Are patients with acute pericardial syndromes adequately screened for connective tissue diseases? Results from a single-centre study and comparison to European Society of Cardiology Guidelines	30
P133 NICE Guidance 41: Is it applicable to a real-world cohort of cervical spine fractures in older people?	30
P143 Frailty is associated with inflammation, impaired glucose metabolism and reduced bone mineral density after adjustment for fat mass index: a UK biobank study	29
OA20 Radiographic hip osteoarthritis classified semi-automatically on dual-energy x-ray absorptiometry scans is strongly predictive of total hip replacement: findings from UK Biobank	29
P085 NRAS New2RA Right Start for people newly/recently diagnosed with RA	29
P299 What happens if the rheumatologist is no longer the gatekeeper to temporal artery ultrasound in giant cell arteritis?	29
P179 A feasibility randomised controlled trial of a fibromyalgia self-management programme in a community setting with a nested qualitative study	28
P086 Patient perceptions of musculoskeletal ultrasound as an educational tool in a rheumatology podiatry clinic	28
P207 NRAS Virtual Groups	28
P019 Rheumatology Referrals to Tertiary Care Hospital over a Three Month Period During Covid-19 Pandemic: a Quality Improvement Project	28
P305 Validating diagnostic GCA ultrasonography skills against an expert sonographer	28
P146 Hepatitis E infection in rheumatic disease: no evidence of chronicity	27
P077 Developing a better explanation of osteoarthritis: results from a conjoint analysis of patient preferences	27
P029 Evaluating the uptake and impact of National Institute for Health and Care Excellence guidance on arthritis	27

P089 Patient-reported outcome measures for rheumatoid arthritis disease activity: a systematic review following COSMIN guidelines	27
P185 Patients' and clinicians' perspectives on the clinical utility of the Rheumatoid Arthritis Foot Disease Activity Index	27
P025 Do referrals to rheumatology meet the new British Society of Rheumatology (BSR) guidelines for adult patients with osteoporosis? A retrospective audit of a tertiary osteoporosis service	27
P065 Post COVID-19 vaccination inflammatory arthritis: a case series of patients at a district general hospital	27
P126 GCA Hospital Standards (GHOST) - making a map of specialised services for the care of giant cell arteritis across England	26
P101 Estimating the quality of life and economic impact of arthritis in Tanzania	26
P119 Average percent fat is associated with decreased bone mineral density at the hip but increase at the spine longitudinally, where weight shows a positive association at all anatomical locations	26
P156 Multidisciplinary paediatric rheumatology clinics	26
P141 What are the predictors of fragility fracture in patients with low body mass index: an observational cohort study	26
Optical spectral transmission to monitor disease activity in arthritis patients: longitudinal follow-up comparison with clinical parameters	26
P060 Pilot study showing the efficacy and acceptability of an acceptance and commitment therapy based brief psychological intervention on mood and disability in patients with early inflammatory arthri	26
Anti-C1q antibodies in IgG4-related disease are common and associated with renal involvement and cutaneous small-vessel vasculitis	26
P038 Let’s look at coxitis features in enthesitis-related arthritis population	26
Combined radiographic and US evaluations to decipher joint involvement in the hands of patients with SSc	26
OA04 COVID-19 admissions and mortality in patients with early inflammatory arthritis: results from a national cohort	26
P089 The cost of repeat ANA testing in north west London pathology services	25
P051 Juvenile Behcet's disease	25
OA34 Post-hoc analysis of spinal MRI SPARCC inflammation scores in patients with radiographic axial spondyloarthritis treated with ixekizumab: results from the COAST-V study at week 16	25
Plasma proteomics for risk prediction and identification of novel drug targets in systemic lupus erythematosus	25
Comment on: ANCA in systemic sclerosis, when vasculitis overlaps with vasculopathy: a devastating combination of pathologies	25
P064 Henoch-Schonlein Purpura: experience of a general pediatric center	25
P131 Adult coeliac disease and bone mineral density at the femoral neck, total hip and lumbar spine: an age- and sex-matched case-control study	25
P010 Clinico-epidemiological characteristics and outcomes of Juvenile Idiopathic Arthritis (JIA) patients in Kenya: data from the KAPRI registry	25
P035 Hip involvement in Tunisian Juvenile Idiopathic Arthritis patients	25
P162 Incidence of neutropaenia and infections in lupus patients on immunosuppression	25
P121 Using patient experiences to redesign health provision - is this the future of rheumatology services?	24
P142 Fracture risk in diabetes: to FRAX or not to FRAX?	24
P218 Drug repurposing screen of Food and Drug Administration-approved medicines identifies novel anti-inflammatory and NF-kB inhibitory activity of the tyrosine kinase inhibitor sunitinib malate	24
OA28 Exploring the potential of polygenic risk scores for predicting coronary artery disease in patients with rheumatoid arthritis	24
P204 Filgotinib demonstrates clinical efficacy in rheumatoid arthritis independent of smoking status: a post-hoc subgroup analysis of three Phase 3 clinical trials	24
P083 Undergraduate rheumatology teaching in the UK: a survey of teachers	24
P138 Real-world incidence and management of hypocalcaemia after denosumab administration in patients with chronic kidney disease: a UK secondary-care based audit	24
P280 Maternal use of hydroxychloroquine with anti-Ro and or anti-La during pregnancy: a systematic review	24
An unusual case of neck pain: crowned dens syndrome	24
P031 Adherence with Methotrexate in Tunisian Juvenile Idiopathic Arthritis Patients	23
P117 Exploring experiences of Fracture Liaison Services and perceptions of a new decision tool to support patient and clinician decisions: a focus group study	23
P107 Improving care for people with chronic low back pain - ESCAPE-pain for back	23
OA06 Clinical outcomes of filgotinib in patients with rheumatoid arthritis aged ≥65 years: a post hoc subgroup analysis of Phase 2 and 3 clinical trials and ongoing long-term extensions	23
P025 Risk assessment of covid 19 in patients with Juvenile Idiopathic Arthritis	23
P042 Using a Genetic PROBability tool (G-PROB) to aid diagnosis of patients with inflammatory arthritis: results from the Norfolk Arthritis Register	23
O13 Which composite measure best reflects disease activity and predicts treatment change in psoriatic arthritis?	23
OA44 Increasing access to rehabilitation for knee and hip osteoarthritis - ESCAPE-pain in leisure/community centres	23
P169 A validated two-score system for interferon is a predictor of response to rituximab in SLE	23
P144 Socioeconomic deprivation is associated with reduced response and lower treatment persistence with anti-TNF therapies in people with rheumatoid arthritis	22
Incidence and risk factors of mental illnesses among patients with systemic autoimmune rheumatic diseases: an 18-year population-based study	22
Prodromal symptoms of rheumatoid arthritis in a primary care database: variation by ethnicity and socioeconomic status	22
IGFBP5 regulates fibrocartilage differentiation and cartilage injury induced by T-2 toxin via blocking IGF-1/IGF-1R signalling	22
Avenciguat: a novel soluble guanylate cyclase activator that affects multiple cell types to inhibit IFN-1 signalling and fibrosis	22
The state of data sharing in rheumatology: a systematic review of top journal practices	22
OA16 Therapeutic certolizumab pegol drug levels to achieve good EULAR response in patients with rheumatoid arthritis: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syn	22
Unveiling the distinctive ossification patterns of diffuse idiopathic skeletal hyperostosis and ankylosing spondylitis using computed tomography three-dimensional reconstruction	22
Correction to: Extended ultrasound examination identifies more large vessel involvement in patients with giant cell arteritis	22
Comment on: Impact of baseline proteinuria level on long-term outcomes in lupus nephritis	22
Treat-to-target in SLE: is serology important? Results from an integrated analysis of five randomized clinical trials of belimumab	22
P128 A subgroup analysis of the efficacy of filgotinib for patients with moderately active RA following an inadequate response to methotrexate	22
OA34 Unravelling the role of B cells and interferon dysregulation in juvenile dermatomyositis	22
Correction to: Unusual histological evidence for anti-neutrophil cytoplasmic antibody associated vasculitis	22
Which advanced treatment should be used following the failure of a first-line anti-TNF in patients with rheumatoid arthritis? 15 years of evidence from the Quebec registry RHUMADATA	22
Prevalence and clinical significance of anti-neutrophil cytoplasmic antibodies in interstitial lung disease: a retrospective cohort study	22
Identification and characteristics of patients with axial psoriatic arthritis: clinical, phenotypic, and imaging associations	22
Withdrawn as duplicate: Transarterial periarticular embolization (TAPE) in checkpoint-inhibitor-associated arthritis—a novel treatment strategy	22
Severe microscopic polyangiitis limited to the skin	21
P210 Tocilizumab versus prednisolone only treatment for giant cell arteritis: an observational study	21
Assessment and diagnosis of the acute hot joint: a systematic review and meta-analysis	21
Dose–response relationships of tea and coffee consumption with gout: a prospective cohort study in the UK Biobank	21
The bidirectional association between chronic musculoskeletal pain and sleep-related problems: a systematic review and meta-analysis	21
P180 Undiagnosed depression in axial spondyloarthropathy negatively affects disease activity and quality of life	21
P081 Unravelling SLE in a young male child	21
Characteristics of patients with difficult-to-treat rheumatoid arthritis in a French single-centre hospital	21
Phenotypic and genotypic characterization of Chinese adult patients with NLRP3-associated autoinflammatory disease with hearing loss	21
Correction to: Vision transformer assisting rheumatologists in screening for capillaroscopy changes in systemic sclerosis: an artificial intelligence model	21
Comment on: Detection of a rare variant in PSTPIP1 through three generations in a family with an initial diagnosis of FMF/MKD-overlapping phenotype	21
Infection is associated with increased risk of MPO- but not PR3-ANCA-associated vasculitis	21
P196 Secukinumab provides sustained improvements in subgroup analyses of joint tenderness and swelling in patients with psoriatic arthritis: 5year results from the Phase3 FUTURE 2 study	20
O007. Register of hereditary auto-inflammatory diseases in a pediatric rheumatology unit	20
Hydroxychloroquine-related hyperpigmentation	20
E15 Immunopositive and immunonegative juvenile idiopathic arthritis: what makes the difference?	20
E40 Chronic recurrent multifocal osteomyelitis: management disease in Tunisian child population	20
P032 Methotrexate and hepatic tolerance in Juvenile Idiopathic Arthritis	20
P080 BSR national training survey results for rheumatology and GIM dual-accreditation	20

P047 Musculoskeletal symptoms as first clinical presentation of juvenile-onset systemic lupus erythematosus: Experience from a military internal medicine department	20
OA04 Impact of pre-operative and perioperative parental preparation on the success of surgery in Tunisian children with scoliosis	20
S100A8/A9 drives monocytes towards M2-like macrophage differentiation and associates with M2-like macrophages in osteoarthritic synovium	20
Tocilizumab-induced organizing pneumonia in a patient with systemic sclerosis–associated interstitial lung disease	20
P028 Impact of Juvenile Idiopathic Arthritis on schooling	20
P096 Pregnancy outcomes in women attending a joint obstetric and rheumatology clinic in a tertiary centre over a 2-year period	20
Call for emergency action to limit global temperature increases, restore biodiversity and protect health	20
E17 Juvenile idiopathic arthritis: are girls less lucky?	19
E44 Differences of hematological abnormalities between COVID-19 infection and multisystemic inflammatory syndrome (MIS-C)	19
P030 Impact of methotrexate on growth in children with Juvenile Idiopathic Arthritis	19
P061 Patient experience of telephone helpline service during the COVID-19 pandemic	19
E37 Clinical and demographic criteria of Juvenile primary systemic vasculitis in Libyan Children	19
E08 Single center study of Systemic Juvenile Idiopathic Arthritis in Moroccan patients	19
E30 Sequelae of Juvenile Idiopathic Arthritis in a 20-year-old young woman	19
E06 Does GGT level correlate with activity parameters in enthesitis-related arthritis?	19
E60 Localized scleroderma and venous thrombosis: an uncommon association in a case report	19
E62 Paediatric rheumatology cases at department of physical medicine/rheumatology Victoria hospital over nine years	19
E42 Severe infectious adverse events in children treated with biological agents	19
Cholesterol crystals in rheumatoid bursal fluid	19
E12 Sleep disturbance among Juvenile idiopathic arthritis patients	19
E56 A 16-year diagnosis delay of a patient with Pigmented Villonodular Synovitis	19
P030 Antiphospholipid syndrome and giant cell arteritis: a coincidence or connection?	18
P159 Factors associated between SLE and work amongst South Asian people: an explorative qualitative study	18
P070 Tele-consultations from the patient’s perspective: during the pandemic and beyond	18
P190 Secukinumab improves back pain, morning stiffness, fatigue and physical function in tumour necrosis factor inhibitor-naive patients with non-radiographic axial spondyloarthritis: results from a r	18
P139 The impact of identifying poor adherence to bone protective treatment via postal questionnaire - Bath Fracture Liaison Service (FLS) audit	18
Comment on: Caffeine improves systemic lupus erythematosus endothelial dysfunction by promoting endothelial progenitor cells survival: reply	18
P127 Treating rheumatoid arthritis patients with moderate disease activity: an analysis of the upadacitinib SELECT Phase III randomised studies	18
P152 The incidence of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies may be higher than we think	18
P076 Adherence to COVID-19 risk stratification during the peak of pandemic: a District General Hospital experience	18
A predictive model based on the gut microbiota improves the diagnostic effect in patients with rheumatoid arthritis	18
New prescribing recommendations bring an opportunity to focus on better reproductive health for women with rheumatic disease	18
The role of IL-23 in joint disease	18
Dry gangrene in cold agglutinin syndrome	18
P053 The place of ASLOs in the diagnosis of RAA in Morocco	18
P010 Management of fibromyalgia patients in secondary care: a retrospective audit	18
Off-label use of biologics in urticarial vasculitis: a European retrospective cohort study	18
Functional autoantibodies in systemic sclerosis: influence of autologous stem cell transplantation and correlation with clinical outcome	17
A systematic review of patient-reported outcome measures in patients with anti-neutrophil cytoplasmic antibody associated vasculitis	17
Assessing the sensitivity and specificity of myositis-specific and associated autoantibodies: a sub-study from the MyoCite cohort	17
CT-based comprehensive scoring system for assessing hip arthropathy in ankylosing spondylitis: feasibility study with clinical correlation	17
Panel sequencing links rare, likely damaging gene variants with distinct clinical phenotypes and outcomes in juvenile-onset SLE	17
Unveiling the dynamics of B lymphocytes in systemic lupus erythematosus patients treated with belimumab through longitudinal single-cell RNA sequencing	17
Occupational impacts of early inflammatory arthritis: results from the National Early Inflammatory Arthritis Audit	17
Relapse after cessation of weekly tocilizumab for giant cell arteritis: a multicentre service evaluation in England	17
Collateral therapy? Clinical remission of ankylosing spondylitis following bone marrow transplant	17
Comparison of two frailty definitions in women with systemic lupus erythematosus	17
Can the dose of belimumab be reduced in patients with systemic lupus erythematosus?	17
Transient osteoporosis of the hip: a novel vascular manifestation of COVID-19?	17
Development of a computed tomography calcium scoring technique for assessing calcinosis distribution, pattern and burden in dermatomyositis	17
The longitudinal study of muscle changes with ultrasound: differential changes in idiopathic inflammatory myopathy subgroups	17
P150 Hand-held dynamometry may provide a valid and objective method of muscle strength quantification in adult inflammatory myopathy: results from clinical practice in a tertiary centre	17
Correction to: Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus	17
Autoantibodies against the melanoma differentiation–associated protein 5 in patients with dermatomyositis target the helicase domains	17
Systemic inflammation in asymptomatic hyperuricaemia with sonographic crystal deposits, including a comparison with normouricaemia and gout	17
VEXAS syndrome through a rheumatologist’s lens: insights from a Spanish national cohort	17
23 Predictive factors of hip involvement in juvenile idiopathic arthritis	16
Rapidly expanding cutaneous Mycobacterium chelonae infection in eosinophilic granulomatosis with polyangiitis	16
P012 Cross-specialty audit of Infliximab prescribing at the Great North Children’s Hospital (GNCH)	16
Kimura’s disease presenting as a posterior mediastinal mass complicated with relapsing polychondritis	16
P188 Secukinumab provides significant improvement of spinal pain and lowers disease activity in patients with axial spondyloarthritis: 24-week results from a randomised controlled Phase 3b trial	16
Editor’s Acknowledgement	16
29 Juvenile idiopathic arthritis and osteogenesis imperfecta: an exceptional association	16
87 Intracerebral inflammatory pseudotumor in Behçet’s disease: a pediatric case report	16
Comment on: Associations between loneliness, disease activity, and disease impact in inflammatory arthritis: a nationwide cross-sectional study among more than 12 000 patients	16
Treatment of moderate rheumatoid arthritis	16
O12 Dactylitis is associated with greater disease severity, CRP, ultrasound determined synovitis, and erosive damage in DMARD-naïve early PsA	16
P132 Redefining refractory disease in RA and adult polyarticular JIA: a Delphi consensus study	16
66 Optic neuritis in children	16
26 Kawasaki’s disease vs systemic juvenile idiopathic arthritis, a diagnostic dilemma	16
75 Juvenile systemic sclerodermas: a case report	16
P045 Octopus Toes?	16
P016 When and how to deliver advice about self-management: local observations from the National Early Inflammatory Arthritis Audit	16
Correction to: Five-year follow-up of patients with difficult-to-treat rheumatoid arthritis	16
P043 Challenges in the diagnosis and management of immune-mediated necrotizing myopathy in a patient on long-term statins	16
88 Tubulointerstitial nephropathy and uveitis (TINU syndrome): a paediatric case report	16
Non-inflammatory pain in inflammatory arthritis	15
Regional differences in clinical phenotype of axial spondyloarthritis: results from the International Map of Axial Spondyloarthritis (IMAS)	15
Highlights from the plenary session: cellular and molecular mechanisms of disease (I)	15
Comment on: Vasculitis associated with VEXAS syndrome	15
Distinct genetic risk loci between biopsy-proven renal and non-renal lupus: a 10-year longitudinal cohort	15
Cardiac MRI optimizes risk stratification accuracy in connective tissue disease-associated pulmonary arterial hypertension: a retrospective cohort study	15
P012 Health inequalities in the diagnosis and treatment of rheumatoid arthritis	15
E035 Tocilizumab and the reversible cerebral vasoconstriction syndrome	15
P018 A review of the use of anakinra in hyperinflammatory conditions at a large central London teaching hospital	15
Tocilizumab and rituximab for systemic sclerosis interstitial lung disease: a real-world cohort analysis	15
Manubriosternal joint destruction with a rheumatoid nodule in rheumatoid arthritis	15
Biopsy vs imaging for the diagnosis of giant cell arteritis. Viewpoint 2: in favour of biopsy	15
P173 The positive utility of PSAID-12 score in remote monitoring and the impact of gender and treatment on patient reported outcomes in psoriatic arthritis	15
Efficient detection of somatic UBA1 variants and clinical scoring system predicting patients with variants in VEXAS syndrome	15
Giant cell arteritis mimics with severe consequences: a long-term monocentric inception cohort	15
Corticosteroid use in PFAPA syndrome: clinical practice data from the JIR-CliPS Survey Study and a comprehensive literature review	15
Approach to Janus kinase inhibition for juvenile dermatomyositis among CARRA and PReS providers	15
Baseline synovitis–tenosynovitis is associated with remission in early rheumatoid arthritis, but discordance with disease activity is a changeable state	15
E019 Management of idiopathic inflammatory myositis - a Northamptonshire audit of British Society for Rheumatology guidelines	15